Skip to main content
NEXTBIOMEDICAL Co., Ltd. logo

NEXTBIOMEDICAL Co., Ltd. — Investor Relations & Filings

Ticker · 389650 ISIN · KR7389650003 KO Manufacturing
Open in API
Filings indexed 56 across all filing types
Latest filing 2024-11-28 Regulatory Filings
Country KR South Korea
Listing KO 389650

About NEXTBIOMEDICAL Co., Ltd.

https://nextbiomedical.co.kr/en/

NEXTBIOMEDICAL Co., Ltd. is a company specializing in the development and commercialization of innovative therapeutic solutions, with a focus on drug-device combination products. The company's core competency is its proprietary polymer technology platform, which includes biodegradable adhesive polymers and resorbable microspheres. These technologies are applied to create first-in-class medical devices that address unmet clinical needs. Key product applications include advanced hemostatic agents for endoscopic procedures and embolic materials for interventional pain management and vascular therapies, such as genicular artery embolization for osteoarthritis pain.

Recent filings

Filing Released Lang Actions
기타경영사항(자율공시) (미국 식품 의약국 (FDA) 의료기기 (2등급) 품목허가 취득)
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement from NextBiomedical regarding the receipt of FDA 510(k) clearance for their medical device 'Nexpowder'. It is a voluntary disclosure (자율공시) of a significant business event. Since it does not fit into specific categories like financial reports, board changes, or share transactions, and serves as a general regulatory update regarding company operations, it is classified as a Regulatory Filing (RNS).
2024-11-28 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea. It details the acquisition of shares in Next Biomedical Co., Ltd. by JPMorgan Asset Management (Asia Pacific) Limited and its special related parties. This type of filing is a regulatory requirement under the Financial Investment Services and Capital Markets Act when an entity crosses a significant ownership threshold (typically 5%). Since it is a formal notification of major shareholding changes, it falls under the 'Major Shareholding Notification' category.
2024-11-15 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'NextBioMedical' covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial information, business operations, management discussions, and corporate governance details, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the acquisition of shares by an executive (Park Se-hwan) through the exercise of stock options. This type of filing is specifically categorized as 'Director's Dealing' (DIRS) as it reports personal share transactions by company directors and executives.
2024-10-07 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a mandatory disclosure of insider transactions, specifically reporting the exercise of stock options by an executive (Lee Eun-hye). In the provided classification schema, reports of personal share transactions by company directors and executives are categorized as 'Director's Dealing'.
2024-10-07 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is a standard regulatory requirement for insiders (directors/executives) to disclose changes in their shareholdings, including stock option exercises. In the provided taxonomy, this corresponds to 'Director's Dealing' (DIRS), which covers insider transactions and ownership changes.
2024-10-07 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.